Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Futibatinib and Pembrolizumab in FGF19+ Advanced HCC
NCT04828486Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Aug 2021
- Primary completion
- Sep 2024
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of futibatinib in hepatocellular carcinoma (HCC), sponsored by Mayo Clinic. Started Aug 2021; status: completed.
02
Drugs
futibatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04828486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04828486.